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Abstract
Background: Changes in blood-brain barrier (BBB) functionality have been implicated in Parkinson’s disease. This
study aimed to investigate BBB transport of L-DOPA transport in conjunction with its intra-brain conversion, in
both control and diseased cerebral hemispheres in the unilateral rat rotenone model of Parkinson’s disease.
Methods: In Lewis rats, at 14 days after unilateral infusion of rotenone into the medial forebrain bundle, L-DOPA
was administered intravenously (10, 25 or 50 mg/kg). Serial blood samples and brain striatal microdialysates were
analysed for L-DOPA, and the dopamine metabolites DOPAC and HVA. Ex-vivo brain tissue was analyzed for
changes in tyrosine hydroxylase staining as a biomarker for Parkinson’s disease severity. Data were analysed by
population pharmacokinetic analysis (NONMEM) to compare BBB transport of L-DOPA in conjunction with the
conversion of L-DOPA into DOPAC and HVA, in control and diseased cerebral hemisphere.
Results: Plasma pharmacokinetics of L-DOPA could be described by a 3-compartmental model. In rotenone
responders (71%), no difference in L-DOPA BBB transport was found between diseased and control cerebral
hemisphere. However, in the diseased compared with the control side, basal microdialysate levels of DOPAC and
HVA were substantially lower, whereas following L-DOPA administration their elimination rates were higher.
Conclusions: Parkinson’s disease-like pathology, indicated by a huge reduction of tyrosine hydroxylase as well as
by substantially reduced levels and higher elimination rates of DOPAC and HVA, does not result in changes in BBB
transport of L-DOPA. Taking the results of this study and that of previous ones, it can be concluded that changes
in BBB functionality are not a specific characteristic of Parkinson’s disease, and cannot account for the decreased
benefit of L-DOPA at later stages of Parkinson’s disease.
Keywords: Population pharmacokinetic modelling, Parkinson’s disease, rat rotenone model, BBB transport, L-DOPA,
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Background
Tyrosine is usually considered as the starting point in
the biosynthesis of dopamine (DA). It is taken up into
the brain and subsequently from brain extracellular fluid
into dopaminergic neurons where its is converted to
3,4-dihydroxyphenylalanine (L-DOPA), by tyrosine
hydroxylase (TH). Aromatic amino acid decarboxylase
(AADC) then converts L-dopa to DA and stored in vesi-
cles for neurotransmission [1]. Dopamine is metabolized
outside the vesicles where monoamine oxidase (MAO)
and aldehyde dehydrogenase transform DA into 3,4-
dihydroxyphenylacetic acid (DOPAC) which then dif-
fuses out of the cells. Subsequently, DOPAC is mainly
transformed to homovanillic acid (HVA) by catechol-O-
methyltransferase (COMT) [2,3].
I ti sk n o w nt h a ti nP a r k i n s o n ’s disease dopaminergic
neurons in the nigro-striatal pathway are progressively
damaged [4], which causes a decrease in dopamine
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kinson’s disease focuses mainly on symptomatic treat-
ment to replace the lost dopamine in the striatum. The
drug that is routinely used for the symptomatic treat-
ment of Parkinsonism is L-3,4-dihydroxyphenylalanine
also known as L-DOPA or levodopa [5]. For patients
with early-stage Parkinson’s disease, the treatment with
L-DOPA is quite successful. However, the benefits of
this drug gradually decline in the later stages [4-9]. It
may be that this decreased benefit of L-DOPA is solely
due to a reduction in the number of viable dopaminer-
gic neurons that can convert L-DOPA into dopamine to
reduce the symptoms. However, it may also be that the
pharmacokinetics of L-DOPA in the brain for the same
dose of L-DOPA may change during disease progres-
sion, due to alterations in the functionality of the blood-
brain barrier (BBB) [10].
The question whether the BBB is affected in Parkin-
son’s disease is still a matter of debate. Results from dif-
ferent investigations in animal models or patients with
Parkinson’s disease vary. Carvey et al.[ 1 1 ]o b s e r v e d
areas of BBB leakage in 6-OH-dopamine-treated rats, in
an acute model for Parkinson’s disease, using FITC-
labelled albumin and horseradish peroxidase.
Furthermore, they found areas with increased
expression of P-glycoprotein (P-gp), and showed that
the dopamine antagonist domperidone, that normally
has highly limited brain distribution due to its high
affinity for P-gp, was able to attenuate apomorphine-
induced stereotypic behaviour in these animals. In
human positron emission tomography (PET) studies,
Bartels et al. found that P-glycoprotein exhibits
decreased function in patients with advanced but not
early Parkinson’s disease [12,13]. The authors sug-
gested that breakdown of the BBB may occur with
increasing severity of the disease. In contrast, in the
unilateral rat rotenone model for progressive Parkin-
son’s disease, no changes in BBB transport were found
for fluorescein [14]. Also, in the primate brain,
Astradson, et al. [15] found no disruption of the BBB
using in vivo neuroimaging techniques with gadoli-
nium-diethylenetriamine pentaacetic acid (Gd-DTPA).
With regard to BBB transport for L-DOPA being
dependent on the L-type amino acid influx transporter
1( L A T 1 )[ 1 6 ] ,i ti so fi n t e r e s tt h a tO h t s u k iet al. [17]
found a ~50% reduction of LAT1 mRNA expression at
the BBB in mice, 7 days after treatment with 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), in
conjunction with motor deficits and a loss of dopami-
nergic neurons. Also, Westin et al. [18] found BBB
defects in the basal ganglia in MPTP lesioned/chronic
L-DOPA-treated animal models of Parkinson’s disease.
Finally, Alexander et al. [19] found an inverse rela-
tionship between the ability of MPTP-treated monkeys
to transport L-DOPA from blood to brain and their
degree of Parkinsonism.
Studies on the potential mutual interactions of BBB
transport, the fate of L-DOPA metabolism in the brain,
and the number of viable dopaminergic neurons under
normal and diseased conditions are needed for improved
understanding of Parkinson’s disease. In this study using
a unilateral rat model of Parkinson’s disease, we charac-
terized the BBB transport of L-DOPA, L-DOPA’s neuro-
pharmacokinetics and its associated conversion, via
dopamine, into the main dopamine metabolites DOPAC
and HVA, in healthy as well as in late-stage diseased
brain. Our hypothesis was that a decrease in BBB trans-
port of L-DOPA would contribute to the decline in L-
DOPA efficacy at later stages of Parkinson’s disease.
In this study, intracerebral microdialysis was used for
the determination of BBB transport of L-DOPA [20]. At
14 days after unilateral rotenone infusion into the med-
ial forebrain bundle (MFB), microdialysate samples were
collected in parallel with serial blood samples. Concen-
trations of L-DOPA, dopamine, DOPAC and HVA con-
centrations were determined in the striatal microdialysis
samples, from both the rotenone-infused and the con-
trol side. These concentrations were determined under
basal conditions as well as following intravenous admin-
istration of 10, 25 or 50 mg/kg of L-DOPA. At the end
of the experiment, brains were removed for TH immu-
nostaining to determine responders and non-responders,
from the percentage loss of dopaminergic terminals in
the striatum. The mutual interactions between the dif-
ferent processes were determined by developing a math-
ematical model on the basis of the interconnected data
obtained.
Methods
Animals and surgical procedures
Animals
All animal procedures described in this paper were
approved by the Ethical Committee on Animal Experi-
mentation of the University of Leiden (DEC numbers
118 and 5069). Experiments were performed on male
Lewis rats (Charles River BV, Maastricht, The Nether-
lands) weighing 311 ± 17 g (mean ± s.d., n = 18) and
288 ± 13 g (mean ± s.d., n = 17) before surgery and
before start of the experiment, respectively. The rats
were housed in standard plastic cages (six per cage
before surgery and individually after surgery) with a 12-
hour day/night schedule (lights on 7:30 a.m.) and at a
temperature of 21°C. The animals had access to stan-
dard laboratory chow (RMH-TM; Hope Farms, Woer-
den, The Netherlands) and acidified water ad libitum.
Surgery
The surgery for the microdialysis study was performed
under anesthesia with an intramuscular injection of 0.1
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Page 2 of 14mg/kg medetomidine hydrochloride (Domitor 1 mg/ml,
Pfizer, Capelle a/d IJssel, The Netherlands) and 1 mg/kg
ketamine base (Ketalar 50 mg/ml, Parke-Davis, Hoofd-
dorp, The Netherlands). Three indwelling cannulae
(pyrogen-free, nonsterile polyethylene tubing, Portex
Limited) were implanted, one in the left femoral artery
for blood sampling and two in the left femoral vein for
drug administration. The cannulae were tunnelled sub-
cutaneously and fixed at the back of the neck with a
rubber ring. The skin in the neck was stitched with nor-
mal sutures. The skin in the groin was closed with
wound clips. To prevent clotting and obstruction, the
cannulae were filled with a 25% (w/v) polyvinylpyrroli-
done solution (PVP; Brocacef, Maarssen, The Nether-
lands) in pyrogen-free physiological saline (B. Braun
Melsungen AG, Melsungen, Germany) containing 20
IU/ml heparin (Hospital Pharmacy, Leiden University
Medical Center, Leiden, The Netherlands).
After the implantation of the intravascular cannulae,
the rats were placed in a stereotaxic frame and the skull
was exposed for brain surgery. The skull was cleaned
and a hole was drilled to allow a needle (30 G, Micro-
lance, Becton Dickinson) to be lowered into the right
MFB using the co-ordiantes AP: -2.8; L: +2.0; V: -9.0
relative to bregma [21] for unilateral infusion of 5.0 μg
of rotenone (Rotenone Pestanal
® Sigma Alldrich BV,
Zwijndrecht, the Netherlands) at a rate of 0.1 μl/min for
30 min. Rotenone was dissolved in a 1:1-mixture of
dimethylsulfoxide (DMSO, Sigma Alldrich BV) with
polyethylene glycol (PEG 200, Sigma Alldrich BV). After
the infusion, the needle was kept in place for another 5
m i nt op r e v e n tl e a k a g ea l o n gt h et r a c ko ft h en e e d l e .
Subsequently, two small holes were drilled into the skull
to allow implantation of the microdialysis guide cannu-
lae (CMA/12, Aurora Borealis Control BV, Schoone-
beek, The Netherlands) in the left and in the right
s t r i a t u m ,A P :+ 0 . 4 ;L :+ / - 3 . 2 ;V :- 3 . 5r e l a t i v et ob r e g m a
[21]. One support screw was placed as an extra anchor
for the guide, which was glued to the skull with dental
acrylic cement (How media simplex rapid + methylacry-
late, Drijfhout, Amsterdam, The Netherlands). After sur-
gery, the rats were allowed to recover for 13 days, after
which they were randomly assigned to one of three dos-
ing groups of 10 mg/kg (n = 4); 25 mg/kg (n = 4); and
50 mg/kg (n = 5) of L-DOPA. The intracerebral unilat-
eral rat rotenone model used in these experiments, has
been described previously by our group [14].
Microdialysis experimental setup
At 13 days after the unilateral infusion of rotenone into
the right MFB, and 18-24 hours prior to the experiment,
the microdialysis probes (CMA12, membrane length of
4.0 mm; Aurora Borealis Control BV) were inserted into
the guide cannulae. All animals were fasted overnight
prior to the experiment in order to rule out any compe-
tition in BBB transport of L-DOPA with food-related
amino acids [22]. The microdialysis experiment, 14 days
post rotenone treatment, was started between 7:00 and
8 : 0 0a . m .T h ei n l e t so ft h em i c r o d i a l y s i sp r o b e sw e r e
connected by FEP tubing (fluorinated ethylene propy-
lene tubing; Aurora Borealis Control BV) to syringe
pumps (Beehive, Bas Technicol, Congleton, United
Kingdom). The probes were perfused with artificial ECF
(composition in mM: NaCl 145; KCl 2.7; CaCl2 1.2;
MgCl2 1.0; ascorbic acid 0.2 in a 2 mM phosphate buf-
fer pH 7.4) [23] at a flow rate of 2 μl/min. The outlets
also consisted of FEP tubing and were connected to a
microsample collector (Univentor 820; Antec, Leiden,
The Netherlands), in which the samples were cooled (4°
C). The vials contained an antioxidant fluid (0.1 M
acetic acid, 3.3 mM L-cysteine, 0.27 M EDTA, 0.0125
mM ascorbic acid dissolved in Millipore water) in a
ratio of 1:4 with the expected volume of the microdialy-
sis sample, to prevent the breakdown of the
catecholamines.
After a stabilisation period of 60 min, the in vivo
recovery of L-DOPA was determined by the retrodialysis
method. For this purpose, the probes were first perfused
with a L-DOPA solution (10, 100 or 200 ng/ml in the
perfusion fluid for the 10, 25 and 50 mg/kg dose groups,
respectively) for 60 min to collect 6 fractions. The rela-
tive loss of L-DOPA was determined and used for esti-
mating brain extracellular fluid (brainECF)
concentrations. After this period, the syringes were
switched to blank perfusion fluid for the washout phase
of 90 min.
After the washout period, the intravenous administra-
tion of L-DOPA was started. One venous cannula was
connected to a syringe containing L-DOPA (Sigma All-
drich BV, Zwijndrecht, the Netherlands) in 0.2 M HCl
in saline (0.9% NaCl) and ascorbic acid (5% of the L-
DOPA amount) and the second venous cannula was
connected to a syringe containing 7% NaHCO3 to neu-
tralize the acidic L-DOPA solution. Both infusions were
started at the same time for 20 min at a rate of 20 μl/
min. In the first 120 min of the experiment, microdialy-
sis fractions were collected at 10-min intervals. From
120-180 min, microdialysis fractions were collected at
20-min intervals. From 180m i nu n t i lt h ee n do ft h e
experiment (at 360 min), microdialysis fractions were
collected at 30-min intervals. Blood samples (50 μli n
heparinised Eppendorf vials) were taken at pre-dose (5
min before), and at 5, 10, 15, 20, 22, 24, 26, 28, 30, 45,
50, 60, 75, 90, 120, 180, 240, 360 min after start of the
L-DOPA infusion. The blood samples were centrifuged
for 10 min at 5000 rpm and the plasma was pipetted
into Eppendorf vials. All samples were stored at - 80°C
before analysis. After the experiment, the animals were
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Ceva Santa Animale, Maassluis, The Netherlands) and
the thorax was opened and the vascular bed was per-
fused via the left ventricle of the heart with 30 ml of sal-
i n ef o l l o w e db y3 0m lo f1 0 %p h o s p h a t eb u f f e r e d
formalin (pH 7.0). Brains were removed for
histopathology.
Immunohistopathology
TH immunohistochemistry was performed to quantify
the degree of dopaminergic depletion as described
previously [14]. After staining, striatal sections were
analysed by measuring the optical density of manu-
ally-defined areas on each black and white image pro-
duced as a mean grey value (MGV). Optical density
was measured for the slide (background), cortex (con-
trol tissue staining), corpus callosum (control non-cel-
lular staining), dorsal striatum (caudate putamen,
CPu) and ventral striatum (nucleus accumbens,
NAcc). The values were adjusted for non-specific
staining by subtracting the MGV of the corpus callo-
sum or cortex. Mean, standard deviation and standard
error of the mean (sem) of MGV was calculated. All
striatal MGV values are corrected for cortical MGV.
The percentage of intact TH staining in the rotenone-
treated hemisphere was calculated as the percentage
of striatal MGV compared to the striatal MGV of the
untreated hemisphere. In the clinical setting, symp-
toms of Parkinson’s disease arise when about 80% of
striatal dopamine and about 60% of dopamine neurons
are lost [4]. The rats which exhibited a TH staining
level lower than 40% (60-100% of the dopamine term-
inals were lost) were considered as ‘responders’ to the
rotenone treatment.
Analysis of L-DOPA, DOPAC and HVA
All plasma samples were analysed for L-DOPA and all
microdialysate samples were analysed for L-DOPA,
dopamine, DOPAC and HVA using a high performance
liquid chromatography (HPLC) system with electroche-
mical detection (ECD).
HPLC and Electrochemical Detection system
The HPLC system consisted of a LC-10AD HPLC pump
(Shimadzu, ‘s Hertogenbosch, The Netherlands), a
Waters 717 Plus autosampler (Waters, Etten-Leur, The
Netherlands), a pulse damper (Antec Leyden, Zoeter-
woude, The Netherlands) and a digital electrochemical
amperometric detector (DECADE, software version 3.02,
Antec Leyden). The electrochemical detector consisted
of a VT-03 electrochemical flow cell combined with a
25 μm spacer and an in situ Ag/AgCl (ISAAC) reference
electrode operating in the DC mode. For the analysis, a
standard Ag/AgCl reference electrode, filled with a satu-
rated KCl solution was used. Data acquisition and
processing was performed using the Empower
® data-
acquisition software (Waters).
Analysis of L-DOPA in plasma
Chromatography of plasma samples of L-DOPA was
performed on a Beckman Coulter™ Ultrasphere
® 5 μm
C-18 column (4.6 mm I.D. × 150 mm, Alltech, Breda,
The Netherlands) equipped with a refill guard column
(2 mm I.D. × 20 mm, Upchurch Scientific, Oak Harbor,
WA, USA) packed with pellicular C18 material (particle
size 20-40 μm, Alltech) at a constant temperature of 30°
C .T h em o b i l ep h a s ew a sam i x t u r eo f0 . 0 5Ms o d i u m
phosphate buffer (pH 2.8) and methanol (90:10, v/v),
supplemented with 0.3 mM EDTA (sodium salt) and 10
mM octane-sulfonic acid. Before the addition of metha-
nol, the mobile phase was filtered through a 0.2 μm
nylon filter (Alltech), then the methanol was added and
it was mixed and degassed with helium. The flow rate
was set at 1 mL/min. The optimal working potential for
L-DOPA was +0.75 V, as determined by a voltammo-
gram and sensitivity plot. Concentrations were measured
at a sensitivity range of 5 nA for L-DOPA and 20 nA for
3,4-dihydroxybenzylamine hydrobromide (DHBA; inter-
nal standard). Stock solutions of L-DOPA were prepared
at a concentration of 1 mg/mL in Millipore water. The
stock solutions were diluted with Millipore water to
obtain calibration solutions in the range of 2 to100 ng/
mL. The internal standard (DHBA) solution was pre-
pared by dilution of the stock solution to a final concen-
tration of 500 ng/mL. The stock solutions were stored at
-80°C for up to one month. The assay solutions were
prepared freshly before each analysis. For determination
of the L-DOPA in plasma, 25 μL of internal standard
solution (DHBA 500 ng/mL) was added to 45 μL plasma
samples and 50 μL of Millipore water in glass centrifuge
tubes. Next, 25 μL of 20% TCA was added and the mix-
ture was vortexed for 5 min. After centrifugation for 10
min at 4000 rpm (2000 g), 100 μL of the supernatant
was added to 50 μL of phosphoric buffer (1 M, pH 5.5)
of which 25 μL was injected into the HPLC system.
Analysis of L-DOPA, dopamine, DOPAC and HVA in
microdialysate
For analysis of L-DOPA, dopamine, DOPAC and HVA
brain microdialysate concentrations, 5 μL of internal
standard (isoproterenol, 100 ng/mL) solution was added
per 10 μL of microdialysis sample or calibration curve
sample. The samples were then injected (20 μL) into the
HPLC system without further sample pre-treatment.
Chromatography of brain microdialysate samples was
performed on a Beckman Coulter™ Ultrasphere
® 5 μm
C-18 column (2 mm I.D. × 250 mm, Alltech) at a con-
stant temperature of 30°C. The mobile phase was a mix-
ture of 0.05 M sodium phosphate buffer (pH 2.8) and
methanol (88:12, v/v), supplemented with 0.3 mM
EDTA (sodium salt) and 1.5 mM octane-sulfonic acid.
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nylon filter. The methanol was added and the mobile
phase was mixed and degassed with helium. The flow
rate was set at 0.2 mL/min. The optimal working poten-
tial for a mixture of L-DOPA, dopamine, DOPAC and
HVA was +0.66 V, as determined by a voltammogram
and sensitivity plot. Concentrations were measured at a
sensitivity range of: 0.1 nA for dopamine, 0.5 nA for L-
DOPA, HVA and isoproterenol; and 10 nA for DOPAC.
For analysis of brain microdialysate samples, stock solu-
tions of L-DOPA, DOPAC and HVA were prepared at a
concentration of 0.5 μg/mL for dopamine, 1 μg/mL for
L-DOPA and 5 μg/mL for DOPAC and HVA in micro-
dialysis perfusion fluid with aqueous antioxidant solu-
tion consisting of 0.1 M acetic acid, 3.3 mM L-cysteine,
0.27 M EDTA (sodium salt) and 0.0125 mM ascorbic
acid (4:1 v/v). Internal standard solution was freshly pre-
pared before each analysis by dilution of a 1 mg/mL iso-
proterenol stock solution, to a concentration of 100 ng/
mL of the compound in perfusion fluid that contains
antioxidant (4:1 v/v). All the stock solutions were stored
at -80°C for up to one month. Before each analysis a
first calibration solution containing all compounds was
f r e s h l yp r e p a r e db ym i x i n go n ev o l u m eo fe a c hs t o c k
solution (L-DOPA, dopamine, DOPAC and HVA) and
adding 5 volumes of perfusion fluid with antioxidant
(6:1 v/v). This first calibration solution now contained
all compounds at a concentration 10 times lower than
their stock solution and from this solution the other
calibration solutions were prepared.
Population pharmacokinetic data analysis- model
development
The pharmacokinetics ofL - D O P A ,D O P A Ca n dH V A
were analysed utilizing a population pharmacokinetic
modelling approach. Dopamine concentrations were all
below the limit of detection. Compartmental modelling
was performed using the ADVAN6 subroutine in NON-
MEM VI release 2 (GloboMax LLC, Hanover, MD,
USA). All fitting procedures were performed on an
IBM-compatible computer (Pentium IV, 1500 MHz)
running under Windows XP with the Compaq Visual
Fortran compiler version 6.6. The inter-individual varia-
bility of model parameters was described by an expo-
nential equation, according to:
P1i = θ1 · exp(ηi),
where θ1 is the population (typical) estimate for para-
meter P1,P 1i is the individual estimate and hi deter-
mines the random deviation of P1i from P1.T h ev a l u e s
of hi are assumed to be randomly, normally distributed
with mean zero and variance ω11
2. The residual error in
the L-DOPA concentration was described by a
proportional error model:
Cobs,ij =C pred,ij · (1 + εij),
and the residual error in the DOPAC or HVA concen-
tration was described by an additive error model:
Cobs,ij =C pred,ij + εij
where Cobs, ij represents the j
th measured L-DOPA,
DOPAC or HVA concentration for the i
th individual
predicted by the model. Cpred, ij represents the predic-
tion of concentration and εij is the deviation of the
model-predicted value from the observed concentration.
The values of ε are assumed to be randomly, normally
distributed with mean zero and variance s
2.
The first order conditional estimation method with
interaction (FOCE interaction) was used in NONMEM
to fit the models to the data and to estimate θ’s, ω
2’s
and s
2’s. Structural model selection for all models was
based on the likelihood ratio test, diagnostic plots
(observed concentrations vs. individual and population
predicted concentrations, conditional weighted residuals
vs. time and predicted concentrations), parameter corre-
lations and precision in parameter estimates. Inclusion
of one parameter into the model was assumed to be sig-
nificant if this led to a decrease of 10.8 points or more
of the minimum value of the objective function (MVOF)
after fitting the model to the data. This corresponds to
a theoretical significance level of p =0 . 0 0 1u n d e rt h e
assumption that the difference in MVOF between two
nested models is c
2 distributed.
In total, the L-DOPA plasma profiles of 13 rats (10
mg/kg, n = 4; 25 mg/kg, n = 4; 50 mg/kg, n = 5), the L-
DOPA brainECF profiles from the control cerebral hemi-
sphere of 12 rats (10 mg/kg, n = 4; 25 mg/kg, n = 3; 50
mg/kg, n = 5) and the L-DOPA brainECF profiles from
the rotenone-treated responder cerebral hemisphere of 7
responder rats (10 mg/kg, n = 1; 25 mg/kg, n = 2; 50
mg/kg, n = 4) were included in the population pharma-
cokinetic analysis.
On the basis of selection criteria, the plasma and brai-
nECF L-DOPA data from the individual rats were simul-
taneously analysed (Figure 1; compartments 1-5). First,
clearances from compartment 1 to 4 (Cl14), compart-
ment 4 to 1 (Cl41), compartment 1 to 5 (Cl15) and
compartment 5 to 1 (Cl51) were assigned in the struc-
tural model to seek for concentration-dependent BBB
transport of L-DOPA via the LAT-1 transporter. How-
ever, although a large range of plasma concentration
data was available (3 dosages of L-DOPA), no asymme-
try in BBB transport could be identified. The model was
therefore simplified to use the inter-compartmental
clearances Q4 and Q5.
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each rat from this analysis and typical values from this
model (Table 1) were then used as input for the subse-
quent analysis of DOPAC (Figure 1; compartments 6
and 8) and HVA (Figure 1; compartments 7 and 9). In
total, the DOPAC and HVA microdialysate concentra-
tions obtained from the control cerebral hemisphere of
12 rats (10 mg/kg: n = 4; 25 mg/kg: n = 3; 50 mg/kg: n
= 5) and the DOPAC and HVA microdialysate concen-
trations from the rotenone-treated responder cerebral
hemisphere of 8 rats (10 mg/kg: n = 2; 25 mg/kg: n = 2;
50 mg/kg: n = 4) were included in the population phar-
macokinetic analysis.
Results
The percentage of intact TH staining in the rotenone-
treated cerebral hemisphere compared to the untreated
hemisphere at the level of the striatum was below 40%
in 12 out of 17 rats (responders), and higher than 90%
in the remaining 5 rats (non-responders). No quantifi-
able concentrations of dopamine could be detected
throughout the experiment (limit of quantification was
0.01 ng/mL in a 20 μl microdialysate sample). A total of
17 rats were used in the microdialysis experiments: n =
6 in the 10- and 25 mg/kg dose group and n = 5 in the
50 mg/kg dose group, where for one rat the microdialy-
sis probe malfunctioned. All microdialysate concentra-
tions of L-DOPA were corrected for the average in vivo
recovery as determined during the retrodialysis period
(30 ± 6%) in order to estimate brainECF concentrations.
The in vivo recovery was equal for the three concentra-
tions of L-DOPA used, and not affected by disease
condition.
Data analysis
L-DOPA pharmacokinetic modeling
The plasma concentration-time profiles for each rat fol-
lowing intravenous infusion of 10, 25, and 50 mg/kg of
L-DOPA are shown in Figure 2. The resulting brainECF
concentration-time profiles of L-DOPA are shown in
Figure 3, for both the control and the responder cere-
bral hemispheres. The L-DOPA concentrations in
plasma and in brainECF were analysed simultaneously.
All structural parameters of the population pharmacoki-
netic model for L-DOPA could be adequately estimated
(Table 1). No dose-dependency was observed in the
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Figure 1 The population pharmacokinetic model for L-DOPA, DOPAC and HVA comprising of three compartments (1-3) describing the
pharmacokinetics of L-DOPA in plasma, two compartments (4 and 5) describing the pharmacokinetics of L-DOPA in brainECF, one for
the control cerebral hemisphere and one for the rotenone-treated responder cerebral hemisphere, two compartments (6 and 8)
describing the kinetics of DOPAC in brainECF, one for the control cerebral hemisphere and one for the rotenone-treated responder
cerebral hemisphere and two compartments (7 and 9) describing the kinetics of HVA in brainECF, one for the control cerebral
hemisphere and one for the rotenone-treated responder cerebral hemisphere. (V = volume of distribution, Q = inter-compartmental
clearance, k = elimination rate constant, Kin = endogenous formation rate constant of L-DOPA.).
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difference could be detected between the inter-compart-
mental clearances Q4 and Q5, the volumes of distribu-
tion V4 and V5 or the elimination rate constants k40
and k50 when these models were fitted to the L-DOPA
brain concentration data. Table 2 shows a summary of
the MVOF and parameter estimates after the different
assumptions (Q4 = Q5, V4 = V5, k40 = k50 or a combi-
nation of any of these). Also, the separate estimate of
endogenous brain production rate of L-DOPA (Kin)f o r
compartment 4 and 5 resulted in similar estimated
values (5.8 min
-1). Striatal brainECF baseline L-DOPA
levels in the rotenone-treated responder cerebral hemi-
sphere were not statistically different (p = 0.07; Welch’s
t-test) from those in the control hemisphere and aver-
aged 0.010 ± 0.004 pmol/mL and 0.024 ± 0.011 pmol/
mL (mean ± SEM), respectively. Therefore, it can be
concluded that no significant difference can be identified
between the pharmacokinetics of L-DOPA in the con-
trol versus the rotenone-treated responder cerebral
hemisphere.
DOPAC and HVA kinetic modeling
Striatal microdialysate baseline DOPAC levels in the
rotenone-treated responder cerebral hemisphere were
about 6 times lower than in the control cerebral hemi-
sphere and averaged 0.2 ± 0.19 pmol/mL and 1.3 ± 0.17
pmol/mL (mean ± SEM), respectively (p-value < 0.01;
Welch’s t-test). Also, striatal microdialysate baseline
HVA dialysate levels in the rotenone-treated responder
cerebral hemisphere were lower (approximately 4 times)
than in the control cerebral hemisphere with respective
values of 0.25 ± 0.14 pmol/mL and 0.9 ± 0.08 pmol/mL
(mean ± SEM), respectively (p-value = 0.02; Welch’st -
test). Figure 4 shows the population predicted microdia-
lysate concentrations of DOPAC and HVA versus time
for a typical rat per dose group. All structural para-
meters of the population kinetic model for DOPAC as
well as for HVA could be adequately estimated (Table
1). No dose-dependency was found in any of the para-
meters for DOPAC or HVA. For DOPAC, k46 and k58
(rate constants which describe the conversion of L-
DOPA, via dopamine, to DOPAC) do not significantly
differ, which means that there appears to be no effect of
disease on the metabolism of L-DOPA via dopamine to
DOPAC. The same can be said for HVA for which k47
and k59 do not significantly differ. On the other hand,
the elimination rate constants were found to be 7-fold
and 2.5-fold higher in the rotenone-treated responder
compared to the control side for DOPAC (k60 and k80)
and HVA (k70 and k90), respectively.
Discussion
In this study using the rotenone-treated rat as a model for
Parkinson’s disease, the relationship between plasma and
Table 1 Population pharmacokinetic parameter estimates
with the corresponding inter-individual coefficient of
variation (CV%) and lower -and upper limit confidence
intervals (LLCI and ULCI).
Parameter Estimate CV% LLCI-ULCI
L-DOPA
Cl (mL/min) 30 21 17 - 43
ω
2 Cl 0.26 59 -0.041 - 0.56
V1 (mL) 98 39 24 - 172
V2 (mL) 157 15 112 - 202
V3 (mL) 599 15 425 - 773
V4 (mL) 13300 25 6810 - 19800
ω
2 V4 0.075 40 0.020 - 0.13
Q2 (mL/min) 22 24 11 - 32
Q3 (mL/min) 11 16 7.5 - 15
Q4 (mL/min) 22 14 16 - 29
Kin (min
-1) 5.8 36 1.7 - 9.8
ω
2 Kin 0.94 41 0.19 - 1.7
Proportional error (plasma) 0.087 15 0.061 - 0.113
Proportional error (ECF) 0.17 21 0.10 - 0.24
Control cerebral hemisphere
DOPAC
Formation k46 (min
-1) 0.000044 28 0.000020 - 0.000068
ω
2 k46 0.50 60 -0.084 - 1.1
k40 (min
-1) 0.53 23 0.29 - 0.77
ω
2 k40 0.42 46 0.045 - 0.80
Elimination k60 (min
-1) 0.0053 17 0.0035 - 0.0071
ω
2 k60 0.19 58 -0.025 - 0.41
Residual error (additive) 0.0020 16 0.0014 - 0.0026
HVA
Formation k47 (min
-1) 0.000023 15 0.000016 - 0.000030
ω
2 k47 0.019 70 -0.0070 - 0.000030
k40 (min
-1) 0.19 16 0.13 - 0.25
k70 (min
-1) 0.0044 12 0.0033 - 0.0054
ω
2 k70 0.14 53 -0.006 - 0.28
Residual error (additive) 0.0028 24 0.0015 - 0.0041
Rotenone-treated responder cerebral
hemisphere
DOPAC
Formation k58(min
-1) 0.000054 51 -0.00000039 - 0.000011
ω
2 k58 1.0 40 0.23 - 1.9
k50 (min
-1) 0.36 55 -0.025 - 0.75
ω
2 k50 0.53 36 0.16 - 0.90
Elimination k80 (min
-1) 0.038 18 0.024 - 0.052
Residual error (additive) 0.0014 51 0.0000020 - 0.0027
HVA
Formation k59(min
-1) 0.000016 42 0.0000028 - 0.000030
ω
2 k59 0.49 65 -0.14 - 1.12
k50(min
-1) 0.14 55 -0.010 - 0.29
Elimination k90 (min
-1) 0.011 39 0.0027 - 0.020
Residual error (additive) 0.0034 41 0.00060 - 0.0061
V = volume of distribution, Q = inter-compartmental clearance, k =
elimination rate constant. Note: V5 = V4, Q5 = Q4 and k50 = k40.
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and its conversion into the dopamine metabolites DOPAC
and HVA, was measured in parallel in the rotenone-trea-
ted responder and control cerebral hemisphere at 14 days
post-rotenone injection. NONMEM was used to develop a
population based pharmacokinetic model. Basal concen-
trations of DOPAC and HVA in striatal microdialysate
were lower in the rotenone-treated responder brain than
in the control brain. Furthermore, it was shown that dis-
ease-related changes were observed in the kinetics of the
dopamine metabolites following L-DOPA administration,
without any changes in BBB transport of L-DOPA.
In our study, following the rotenone infusion in the
M F Bo ft h er a t s ,t h eP a r k i n s o n ’s disease state was
defined as TH immunostaining in the striatum with a
density of less than 40% of control values (termed
responders). Data indicated that the number of respon-
ders in this model was similar to our previous study
[14], and the disease pathology was successfully induced
in 70% of the rats. It would be of interest to have more
information on potential changes in the pharmacoki-
netics, BBB transport and conversion of L-DOPA at dif-
ferent stages of Parkinson’sd i s e a s e .I nt h i ss t u d yt h e
TH% values found at 14 days following rotenone treat-
ment were either close to 100% (non-responders) or
smaller than 40% (responders; Figure 5), leaving too
small a range to investigate the TH% as a covariate in
the model. A shorter interval between rotenone treat-
ment and experiment might have resulted in more
diverse values for TH%.
50 150  250  350 
50 150  250  350 
50 150  250  350 
Time (min) 
10 
-3.0 
10 
-2.0 
10 
-1.0 
10 
0.0 
10 
1.0 
10 
2.0 
p
l
a
s
m
a
 
L
-
D
O
P
A
 
(
u
g
/
m
L
)
 
10 mg/kg  25 mg/kg  50 mg/kg 
Figure 2 L-DOPA concentration-time profiles in plasma, obtained after a 20-min intravenous infusion in Lewis rats. Depicted are the
observed concentrations (dots) and individual predictions (solid lines), separated by L-DOPA dose (in total 13 rats: 10 mg/kg, n = 4; 25 mg/kg, n
= 4; 50 mg/kg, n = 5).
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Page 8 of 14L-DOPA kinetics in plasma
The results described in this paper are the first in which
both plasma and brainECF pharmacokinetics of L-DOPA
in control and rotenone-treated conditions are described
by a population pharmacokinetic model. The pharmacoki-
netics of L-DOPA in plasma following intravenous admin-
istration was best described by a three-compartmental
model, like previously reported [24]. In our study, we were
not able to measure endogenous plasma concentrations of
L-DOPA (LLQ was 1 ng/mL). Sato et al.[ 2 5 ]f o u n di n
their rat study a basal level of 2.1 ± 0.6 mg/L. In our study,
rats were fasted overnight which might be the reason for
much lower endogenous L-DOPA in plasma. The total
clearance of exogenous plasma of L-DOPA in the study by
Sato et al. [26] was 3.1 L/h/kg, which is in the same order
of magnitude as our value of 6.3 L/h/kg (Cl = 30 mL/min,
Table 1; mean weight of the rats before start of the experi-
ment was 288 ± 13 g).
L-DOPA BBB transport
No difference in BBB transport of L-DOPA between the
control and rotenone-treated responder cerebral hemi-
sphere were found. This is in contrast to the findings of
an inverse relationship between the MPTP-monkeys’
ability to transport L-DOPA from blood to brain and
their degree of Parkinsonism by Alexander et al.[ 1 9 ] .
This may be due to species differences as well as differ-
ences in the disease conditions.
L-DOPA endogenous kinetics
Also, our results did not indicate a disease-induced
change in the endogenous production of L-DOPA in the
brain (Kin; 5.8 min
-1). Since dopamine-producing neu-
rons are diminished in Parkinson’s disease [4], one
would expect a decrease in the endogenous concentra-
tion of L-DOPA, as it is a product of the metabolism of
L-tyrosine by TH. However, it has been reported that
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Figure 3 L-DOPA concentration-time profiles in brainECF in the control cerebral hemisphere (○;i nt o t a l1 2r a t s :1 0m g / k g ,n=4 ;2 5
mg/kg, n = 3; 50 mg/kg, n = 5) and in the rotenone-treated responder cerebral hemisphere (￿; in total 7 rats: 10 mg/kg, n = 1; 25
mg/kg, n = 2; 50 mg/kg, n = 4), obtained after a 20-min intravenous infusion in Lewis rats.
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mine loss, is up-regulated in the striatum of 6-OHDA-
lesioned rats and of MPTP-treated rhesus monkeys [27].
This phenomenon was assumed to be a compensatory
mechanism of the remaining dopaminergic neurons trig-
gered by the synaptic dopamine loss [28]. It may as well
be the case in our situation that up-regulation of TH in
the rotenone-treated responder brain is the reason for
the absence of disease-induced changes in L-DOPA con-
centrations in the brain.
L-DOPA brain metabolism to DOPAC and HVA
The main metabolite of L-DOPA in the early phase after
drug administration is dopamine [29,30], which is
further metabolized to mainly DOPAC and HVA. The
metabolism of L-DOPA via dopamine to DOPAC in the
control cerebral hemisphere (0.000044 min
-1) was indis-
tinguishable from that of the rotenone-treated responder
brain (0.000054 min
-1). Also, the metabolism of L-
DOPA via dopamine to HVA in the untreated brain
(0.000023 min
-1)w a ss i m i l a rt ot h a ti nt h er o t e n o n e -
treated responder cerebral hemisphere (0.000016 min
-1).
Furthermore, these values reflect a slow conversion of
L-DOPA-via dopamine- to these metabolites. Overall, in
contrast to our expectations, it can be said that the dis-
ease conditions at 2 weeks post-rotenone-injection into
the MFB did not result in any change in the pharmaco-
kinetics of L-DOPA.
Baseline DOPAC and HVA
The baseline concentrations of DOPAC and HVA were
decreased about 10-fold in the rotenone-treated responder
brain (Figure 4). These findings are similar to what has
been reported in other studies in rats, after an intracereb-
ral injection of rotenone into the MFB [31] and after intra-
cerebral 6-OHDA injection [32,33]. As no changes in
formation rate constants of DOPAC and HVA (k46 and
k58 for DOPAC, and k47 and k59 for HVA; see Table 1)
were found in the rotenone-treated responder relative to
the control cerebral hemisphere, a decrease in baseline
concentrations results solely from increased elimination
rate constants for DOPAC and HVA.
DOPAC and HVA following administration of L-DOPA
Following L-DOPA administration, differences were
found in DOPAC and HVA concentrations and in rate
Table 2 Summary of goodness-of-fit based on the minimum value of objective function (MVOF), of eight assumptions
within the modeling of L-DOPA in plasma and brainECF.
Assumption Results MVOF V4 V5 Q4 Q5 K40 K50
NONE general -2814 11100 16100 20,9 25,3 0,211 0,135
SE 3840 6970 3,74 9,24 0,033 0,0132
CV(%) 34,6 43,3 17,9 36,5 15,6 9,78
V5 = V4 general -2808 12700 22,9 20,1 0,193 0,161
SE 5700 4,33 7,13 0,0329 0,0185
CV(%) 44,9 18,9 35,5 17 11,5
k50 = k40 general -2803 13200 12000 20,1 26 0,175
SE 3870 4990 3,36 8,77 0,0226
CV(%) 29,3 41,6 16,7 33,7 12,9
Q5 = Q4 general -2813 11400 14400 22 0,211 0,135
SE 3080 3700 3,18 0,027 0,0127
CV(%) 27 25,7 14,5 12,8 9,41
V5 = V4 & k50 = k40 general -2804 13000 21,4 24,3 0,179
SE 3410 3,2 5,56 0,0199
CV(%) 26,2 15 22,9 11,1
V5 = V4 & Q5 = Q4 general m.t. 13000 22 0,19 0,17
S E - - --- -
CV(%) - - - - - -
k50 = k40 & Q5 = Q4 general -2801 13900 10600 21,7 0,173
SE 8290 6610 7,79 0,0276
CV(%) 59,6 62,4 35,9 16
V5 = V4 & k50 = k40 & Q5 = Q4 general -2801 13300 22,4 0,175
SE 3310 3,17 0,0201
CV(%) 24,9 14,2 11,5
The assumption ‘NONE’ is where all parameters were estimated.
V = volume of distribution, Q = inter-compartmental clearance, k = elimination rate constant
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Figure 4 Population predicted concentrations of DOPAC (panel A) and HVA (panel B) in the control cerebral hemisphere (-) and
rotenone-treated responder cerebral hemisphere in responders (—) according to the model as described in Figure 1, at three doses
of L-DOPA.
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TH staining (%).
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Page 12 of 14constants for elimination. In our model, the metabolism
from dopamine to DOPAC and HVA was explained by
first-order kinetics (Figure 1, Table 1), as in the model
previously developed [25,26]. Following L-DOPA
administration, for DOPAC the elimination rate con-
stant in the rotenone-treated responder cerebral hemi-
sphere (0.038 min
-1)w a si n c r e a s e da b o u t7 - f o l d
compared with the elimination rate constant in the
control side (0.0053 min
-1). For HVA this disease-
induced increase was about a factor 2.5 (0.011 min
-1
for the rotenone-treated responder and 0.0044 min
-1
for the control cerebral hemisphere). With unchanged
values for the formation rate constants (k46 and k58
for DOPAC, and k47 and k59 for HVA; see Table 1)
and lower baseline concentrations measured for both
DOPAC and HVA, the higher elimination rate con-
stant as found for DOPAC and HVA would be possible
if dopamine concentrations were lower in the rote-
none-treated responder cerebral hemisphere such that
metabolite formation rate-dependent elimination
occurs. This is also called “flip-flop kinetics” [34], i.e.
[metabolite formation rate constant × amount of meta-
bolite remaining to be formed] is about equal to the
[metabolite elimination rate constant × amount of
metabolite remaining to be eliminated]). Reduced
dopamine concentrations in the rotenone-treated
responder cerebral hemisphere are indeed plausible
with a diminished amount of dopaminergic neurons as
indicated by substantially decreased TH staining.
A number of processes may contribute to the elimina-
tion of DOPAC and HVA from the brain. Elimination
of DOPAC may occur by conjugation, in rats mostly to
sulphates [35], or by transformation to HVA by cate-
chol-O-methyltransferase. For HVA, formed as metabo-
lite of DOPAC but also directly from dopamine [36-38],
the mechanisms of elimination from the brain are not
fully clear. HVA may leave the brain by passive diffusion
[38]. Also, HVA leaves the brain via a probenecid-sensi-
tive organic anion transport (OAT3) system, present at
the BBB [39]. This HVA efflux transport system is likely
to play an important role in controlling the level of
HVA in the brain. An apparent in vivo efflux rate con-
stant of HVA from the brain was determined by Mori et
al.[ 3 6 ]a n df o u n dt ob e0 . 0 1 7m i n
-1.O u rv a l u ef o rt h e
elimination rate constant of HVA in the control cerebral
hemisphere was 0.044 min
-1 and of the same order of
magnitude.
Although the expression of OATs is affected (mainly
down-regulated) in certain renal and hepatic diseases
[40], to our knowledge, no studies have been per-
formed indicating changes in OAT functionality at the
BBB. The increased values that we found for the elimi-
nation rate constants for DOPAC and HVA could have
been the result of up-regulation of one or more of
active elimination processes that we are not yet able to
specify.
In general, the integrated approach used in this study,
including plasma pharmacokinetics, BBB transport and
in vivo assessment of dopamine system functionality at
different stages of the disease may help to unravel more
mechanistically the factors that play a role in effective
Parkinson’s disease treatment.
Conclusions
The developed population pharmacokinetic model
allowed the integration of the kinetics of L-DOPA and
its conversion to DOPAC and HVA in both control and
rotenone-treated responder brain. It was demonstrated
that 2 weeks following a unilateral infusion of rotenone
into the rat brain, dopamine depletion resulted in lower
brain levels and higher elimination rates of DOPAC and
HVA for the diseased cerebral hemisphere. This was,
however, not accompanied by changes in the plasma
pharmacokinetics and BBB transport of L-DOPA. Taken
together, the varying results on whether or not changes
in BBB transport in Parkinson’s disease in previous stu-
dies and in this study indicate that changes in BBB func-
tionality are not specifically associated with Parkinson’s
disease, and therefore cannot account for the decreased
benefit of L-DOPA at later stages of Parkinson’s disease.
List of abbreviations
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